These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 30325657)

  • 21. Hematological changes during androgen deprivation therapy.
    Grossmann M; Zajac JD
    Asian J Androl; 2012 Mar; 14(2):187-92. PubMed ID: 22231300
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transfusion-dependent anemia after initiation of androgen deprivation therapy for metastatic prostate cancer.
    Curtis KK; Pruthi RK; Fonseca R; Gornet MK
    Urology; 2007 Oct; 70(4):811.e5-8. PubMed ID: 17991572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
    BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy.
    Shiota M; Endo S; Fujimoto N; Tsukahara S; Ushijima M; Kashiwagi E; Takeuchi A; Inokuchi J; Uchiumi T; Eto M
    Urol Oncol; 2020 Nov; 38(11):849.e11-849.e18. PubMed ID: 32712140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deficiency in androgens and upregulation of insulin-like growth factor-1 are involved in high bone turnover in men receiving androgen deprivation therapy for prostate cancer.
    Ishizaki F; Hara N; Takizawa I; Nishiyama T; Isahaya E; Kawasaki T; Takahashi K
    Growth Horm IGF Res; 2012; 22(3-4):122-8. PubMed ID: 22579549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study.
    Schmitz-Dräger BJ; Mühlich S; Lange C; Benderska-Söder N; Bismarck E; Starlinger R; Ottillinger B; Hakenberg OW
    Urol Int; 2021; 105(5-6):436-445. PubMed ID: 33631760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Testosterone Reduction of ≥ 480 ng/dL Predicts Favorable Prognosis of Japanese Men With Advanced Prostate Cancer Treated With Androgen-Deprivation Therapy.
    Yamamoto S; Sakamoto S; Minhui X; Tamura T; Otsuka K; Sato K; Maimaiti M; Kamada S; Takei A; Fuse M; Kawamura K; Imamoto T; Komiya A; Akakura K; Ichikawa T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1107-e1115. PubMed ID: 28882738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
    Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
    Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life in prostate cancer patients taking androgen deprivation therapy.
    Dacal K; Sereika SM; Greenspan SL
    J Am Geriatr Soc; 2006 Jan; 54(1):85-90. PubMed ID: 16420202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective evaluation of testosterone fluctuations during a transition of therapy from degarelix to leuprolide in patients on androgen deprivation therapy.
    Zuckerman JM; Eure G; Malcolm J; Currie L; Given R
    Urology; 2014 Mar; 83(3):670-4. PubMed ID: 24360065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
    Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
    Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study.
    Schweizer MT; Wang H; Luber B; Nadal R; Spitz A; Rosen DM; Cao H; Antonarakis ES; Eisenberger MA; Carducci MA; Paller C; Denmeade SR
    Prostate; 2016 Sep; 76(13):1218-26. PubMed ID: 27338150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum testosterone before and during androgen-deprivation therapy, and prognosis between cigarette smokers and nonsmokers with metastatic prostate cancer.
    Shiota M; Kashiwagi E; Murakami T; Takeuchi A; Imada K; Inokuchi J; Tatsugami K; Eto M
    Andrologia; 2018 Dec; 50(10):e13119. PubMed ID: 30084497
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decrease in lean body mass in men with prostate cancer receiving androgen deprivation therapy: mechanism and biomarkers.
    Hara N; Ishizaki F; Saito T; Nishiyama T; Kawasaki T; Takahashi K
    Urology; 2013 Feb; 81(2):376-80. PubMed ID: 23374809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Actin alpha cardiac muscle 1 gene expression is upregulated in the skeletal muscle of men undergoing androgen deprivation therapy for prostate cancer.
    Cheung AS; de Rooy C; Levinger I; Rana K; Clarke MV; How JM; Garnham A; McLean C; Zajac JD; Davey RA; Grossmann M
    J Steroid Biochem Mol Biol; 2017 Nov; 174():56-64. PubMed ID: 28756295
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy.
    Morote J; Esquena S; Abascal JM; Trilla E; Cecchini L; Raventós CX; Catalán R; Reventós J
    Int J Biol Markers; 2005; 20(2):119-22. PubMed ID: 16011042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Association of A Number of Risk Factors With Depression in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy.
    Kim CH; Kim KT; Oh JK; Chung KJ; Kim TB; Jung H; Yoon SJ; Kim KH
    Urol J; 2018 May; 15(3):104-108. PubMed ID: 29388185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Large institutional variations in use of androgen deprivation therapy with definitive radiotherapy in a population-based cohort of men with intermediate- and high-risk prostate cancer.
    Ong WL; Foroudi F; Evans S; Millar J
    BJU Int; 2017 Nov; 120 Suppl 3():35-42. PubMed ID: 28749017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum testosterone levels after medical or surgical androgen deprivation: a comprehensive review of the literature.
    Nishiyama T
    Urol Oncol; 2014 Jan; 32(1):38.e17-28. PubMed ID: 23769268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.